



161
4-111

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/675,943
		Filing Date	September 28, 2000
		First Named Inventor	Angelika Esswein
		Art Unit	1626
		Examiner Name	L. Stockton
Total Number of Pages in This Submission	27	Attorney Docket Number	20496 US1

ENCLOSURES (Check all that apply)				
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):		
		Remarks		
		Further Petition to Revive Unavoidably Abandoned Patent Application Under 37 CFR §1.137(a)		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	John P. Parise
Signature	
Date	June 12, 2003

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date: June 12, 2003	
Typed or printed	John P. Parise
Signature	
Date	June 12, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

BEST AVAILABLE COPY

In re Patent Application



Esswein et al

Serial No.: 09/675,943, filed Sept. 29, 2000

Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley, NJ 07110
June 12, 2003

For: **OSTEOBLAST-SPECIFIC MITOGENS AND DRUGS CONTAINING SUCH COMPOUNDS**

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

DEPOSIT ACCOUNT
NO. 08-2525
OUR ORDER NO. 4957

Transmitted herewith is an amendment in the above-identified application.

page(s) of substitute Sequence Listing.

computer disk(s) containing substitute Sequence Listing.

Statement under 37 CFR §1.825(b) that the computer disk and paper copies of the substitute Sequence Listing are the same.

Statement under 37 CFR §1.825(a) that the substituted Sheets of the Sequence Listing are supported in the application.

No additional fee is required.

Petition for an extension of time under 37 CFR §1.136.

(Col. 1)	(Col. 2)	(Col. 3)			
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE
TOTAL 85	MINUS	98		x \$18	
INDEP. 37	MINUS	4	33	x \$84	2772
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			+ 280		
TOTAL					\$2772

Serial No.
Filed:


X

Please charge my Deposit Account No. 08-2525 in the amount of \$ 2772.00. This sheet is provided in duplicate.

X

A check in the amount of \$ is attached.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525. This sheet is provided in duplicate.



Attorney of Record
John P. Parise
(Reg. No. 34403)
Telephone: (973) 235-6326
Telefax: (973) 235-2363

131345